MARKET

PTCT

PTCT

Ptc Therapeutics
NASDAQ
74.68
+2.32
+3.21%
After Hours: 75.50 +0.82 +1.10% 18:50 02/06 EST
OPEN
73.77
PREV CLOSE
72.36
HIGH
75.00
LOW
72.64
VOLUME
1.04M
TURNOVER
--
52 WEEK HIGH
87.50
52 WEEK LOW
35.95
MARKET CAP
6.00B
P/E (TTM)
8.75
1D
5D
1M
3M
1Y
5Y
1D
PTC Therapeutics Inc. hat eine Aktualisierung ihres Finanzkalenders veröffentlicht
Reuters · 2d ago
PTC Therapeutics Inc. to Report Fourth Quarter and Full Year 2025 Financial Results
Reuters · 2d ago
PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026
PR Newswire · 2d ago
Weekly Report: what happened at PTCT last week (0126-0130)?
Weekly Report · 5d ago
PTC Therapeutics price target raised to $97 from $96 at BofA
TipRanks · 01/30 14:17
Citi Keeps Their Hold Rating on PTC Therapeutics (PTCT)
TipRanks · 01/30 14:16
Converging Analyst Upgrades on PTC’s Rare Disease Pipeline Might Change The Case For Investing In PTC Therapeutics (PTCT)
Simply Wall St · 01/30 04:46
PTC Therapeutics price target raised to $75 from $63 at TD Cowen
TipRanks · 01/29 14:41
More
About PTCT
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).

Webull offers PTC Therapeutics, Inc. stock information, including NASDAQ: PTCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTCT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PTCT stock methods without spending real money on the virtual paper trading platform.